Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

Apalutamide

Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle

DRUG

Carotuximab

"Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose."

Trial Locations (3)

84112

RECRUITING

Huntsman Cancer Institute and Hospital, Salt Lake City

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

91010

RECRUITING

City of Hope, Duarte

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Enviro Therapeutics, Inc.

UNKNOWN

lead

Edwin Posadas, MD

OTHER

NCT05534646 - Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter